Five Health Startups Raise $200M+, From ALS Gene Therapy to AI Billing
Five health companies raised a combined $200 million or so on November 10 and 11. They fall neatly into two camps.
On one side are the drug developers. VectorY Therapeutics is working on gene therapies for ALS and other brain diseases, and PsiThera is designing pills for immune disorders. These are long, expensive, science-heavy bets that can take a decade to pay off.
On the other side are companies using AI to fix how healthcare runs. Charta Health checks medical charts to get billing right. Zus Health pulls scattered patient data together. Kardi Ai, a smaller Czech startup, uses AI to monitor heart rhythms over long periods.
Both camps are attracting money, but for very different reasons. Here's what each company is doing.
VectorY Therapeutics: €74.5 million for antibody gene therapy
VectorY Therapeutics added €74.5 million, about $83.5 million, to its Series A, Endpoints News reported on November 11. It's the largest health round in this group.
The full investor list sits behind a paywall, so the lead hasn't been confirmed in public reporting.
VectorY's approach is unusual. Most antibody drugs are made in a factory and injected into the body, where they have a hard time crossing into the brain. VectorY instead uses gene therapy to get the brain to make the antibodies itself.
If it works, patients could get a steady supply of treatment exactly where it's needed, possibly from a single dose.
Its lead candidate, VTx-002, targets ALS, the fatal nerve disease that has very few effective treatments. The drug is set to enter a clinical trial called PIONEER-ALS. Raising more money inside a Series A, rather than starting a new round, usually means a company needs more runway to reach its next big milestone, which here is clinical data.
PsiThera: $25 million for immune-disease pills
PsiThera, based in Watertown, Massachusetts, closed a $25 million financing. Existing lead investors Samsara BioCapital and Lightstone Ventures returned, and AbbVie Ventures and Lumination Capital joined as new backers.
PsiThera uses biophysics and computational design to develop oral drugs for immune and inflammatory diseases. Its early work focuses on TNF-alpha, TL1A and IL-6, three proteins that drive inflammation in conditions like rheumatoid arthritis and inflammatory bowel disease.
Many of today's treatments that block these targets are injections. A pill that does the same job would be much easier for patients, and that convenience is worth a lot commercially. AbbVie, maker of the blockbuster injectable Humira, joining the round makes that point clearly.
Charta Health: $55 million to get medical billing right
San Francisco-based Charta Health raised a $55 million Series B led by Insight Partners, bringing its total funding to $85 million.
Charta's AI reviews medical charts to help providers and insurers bill accurately. That might sound dry, but billing is one of the most expensive and frustrating parts of American healthcare. Doctors document a visit, coders translate it into billing codes, and insurers check those codes against the record. Mistakes go both ways. Hospitals miss revenue for care they actually provided, and insurers pay for things that weren't properly documented.
Chart review today is mostly done by trained staff reading records line by line. Software that can check every chart, not just a sample, has an obvious payoff for both sides. That's why Charta can sell to providers and insurers at the same time, which is rare in this industry.
Zus Health: $33 million to connect patient data
Boston-based Zus Health raised a $33 million Series B led by Drive Capital. Its total funding is now over $100 million.
Zus tackles another long-running healthcare problem: patient data is spread everywhere. A single patient might have records at a primary care clinic, two hospitals, a lab and a pharmacy, all in different systems. Zus pulls that data together and gives healthcare companies tools to build clinical workflows on top of it, increasingly with AI.
The AI angle matters here.
Any AI tool that helps a doctor is only as good as the data it can see. A model that misses half a patient's history will make bad suggestions. By focusing on the data layer, Zus is positioning itself as the plumbing that other health AI products depend on.
Kardi Ai: €5.3 million for long-term heart monitoring
Czech medtech startup Kardi Ai raised a €5.3 million Series A, about $6.1 million, led by Callisto Health, a German healthtech fund.
Kardi Ai's system combines a fitness-style chest strap fitted with an ECG sensor, a mobile app and AI analysis. It's built to track heart rhythm over long periods and flag signs of possible rhythm disorders. The company is careful to say its product doesn't diagnose anything. It surfaces warning signs so a doctor can take a closer look.
That focus on long-term monitoring makes sense. Heart rhythm problems like atrial fibrillation often come and go, so a short test in a clinic can miss them completely.
A comfortable device people can wear for weeks has a much better chance of catching an episode. Kardi Ai is the smallest company in this group, but it's working on a problem that affects millions of people.
What this mix says about health investing
The five rounds side by side:
Company | Focus | Round | Amount | Lead(s) | Base |
VectorY Therapeutics | Gene therapy for ALS | Series A extension | ~$83.5M (€74.5M) | Not disclosed | Amsterdam |
Charta Health | AI chart review for billing | Series B | $55M | Insight Partners | San Francisco |
Zus Health | Connected patient data | Series B | $33M | Drive Capital | Boston |
PsiThera | Oral drugs for immune disease | Financing | $25M | Samsara BioCapital, Lightstone Ventures | Watertown, MA |
Kardi Ai | AI heart rhythm monitoring | Series A | ~$6.1M (€5.3M) | Callisto Health | Czech Republic |
The split between drug developers and AI operations companies shows two different ways investors are approaching health right now.
The operations companies, Charta and Zus, offer something investors love: a clear path to revenue. Hospitals and insurers already spend huge sums on billing staff and data integration. If software saves them money this year, they'll buy it this year. That's a much shorter loop than drug development.
The drug developers are a longer, riskier bet. VectorY and PsiThera won't make money until their drugs clear trials and win approval, which could take many years. But the potential payoff is huge, and big pharma is watching closely.
AbbVie's venture arm backing PsiThera shows how large drug makers use startups to scout what comes next.
For founders in health, the takeaway is that both paths are fundable, but the pitch has to match the path. An AI operations company needs to show fast savings and happy customers. A biotech needs strong science and a credible route to the clinic. Mixing up those stories is one of the quickest ways to lose an investor's attention.
